Tumor antigen based on products of the tumor suppressor gene wt1
AssigneeInternational Institute of Cancer Immunology, Inc.
InventorsHaruo SUGIYAMA, Yoshihiro Oka
Life of this patent
Estimating the term…
Abstract
A tumor antigen that comprises, as an active ingredient, a product of the Wilms' tumor suppressor gene WT1 or a peptide composed of 7-30 contiguous amino acids containing an anchor amino acid for binding to major histocompatibility complex (MHC) class I in said amino acid sequence, and a vaccine comprising said antigen.
Claims9
-7. (canceled)
An in vivo method of killing target cells that express a polypeptide comprising the amino acid sequence of SEQ ID NO:
- 5, comprising administering to a patient an anti-target cell immune response eliciting amount of a peptide of derived from the amino acid sequence of human WT-1 polypeptide having 9 to 30 amino acids, wherein the peptide comprises the amino acid sequence Arg Met Phe Pro Asn Ala Pro Tyr Leu (SEQ ID NO:5), and wherein the peptide binds to HLA-A0201, and wherein the peptide is processed by HLA-A0201-positive antigen presenting cells to produce the sequence of SEQ ID NO:
- 5 that is capable of eliciting the production of a cytotoxic lymphocyte (CTL) wherein the CTL recognizes a HLA-A0201-positive cell which expresses intact human WT-1 protein.
An in vivo method of killing target cells that express a polypeptide comprising the amino acid sequence of WT-1 comprising administering to a patient an anti-target cell immune response eliciting amount of a peptide of SEQ ID NO:
- 5.
Dependencies are inferred from the claim text.